Dosing & Uses
Anemia of Chronic Kidney Disease
Pending FDA approval for treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients
Next:
Pharmacology
Mechanism of Action
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI); promotes coordinated erythropoiesis through increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
